

HEALTHY U MEDICAID

PRIOR AUTHORIZATION REQUEST FORM

XHANCE®

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred: fluticasone propionate nasal spray mometasone nasal spray

Non-preferred: Xhance® (fluticasone propionate)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Does the member have a diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) or chronic rhinosinusitis without nasal polyposis?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Is the request being made by or in consultation with an allergist, ENT specialist, or pulmonologist?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Is the member at 18 years of age or older?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Does documentation show a 3-month trial and failure of or contraindication/intolerance to BOTH of the following intranasal steroids? <ul style="list-style-type: none"> • fluticasone propionate 50 mcg/actuation nasal spray • mometasone furoate 50 mcg/actuation nasal spray 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. For chronic rhinosinusitis with nasal polyposis (CRSwNP) : Does documentation show diagnosis confirmed by one of the following: <ul style="list-style-type: none"> • Anterior rhinoscopy • Nasal endoscopy • Computed tomography (CT) 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

6. For chronic rhinosinusitis without nasal polyposis: Does documentation show the member has at least two of four cardinal symptoms: nasal obstruction, anterior or posterior nasal discharge, reduction or loss of smell, and facial pain/pressure/fullness for at least 12 weeks duration?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
7. For chronic rhinosinusitis without nasal polyposis: Does documentation include objective evidence of mucosal inflammation, either by direct visualization or on an imaging study (sinus computed tomography [CT] scan)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
REAUTHORIZATION			
1. Is the requesting for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member's therapy been re-evaluated within the past 6 months?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Has the therapy shown to be effective with an improvement in condition?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does the member show a continued medical need for the therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

****Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-HU-086
 Origination Date: 01/01/2022
 Reviewed/Revised Date: 05/22/2024
 Next Review Date: 05/22/2025
 Current Effective Date: 06/01/2024

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.